Comments 1 - 16 of 16 Search these comments
We'll bike the 7-10 minutes to our volleyball pub if it's warm enough.
WookieMan says
We'll bike the 7-10 minutes to our volleyball pub if it's warm enough.
Isn't that the solution to that issue you wrote about in a previous post about the risk of driving home when you have had a few beers at the volleyball club?
. By far the most frequent request was for gastric bypass (I can't remember the medical term that applied), a $40K procedure then. Intracorp had the policies for CONY, the employees of the City of New York. You would not believe how many people requested this procedure,
Someone's fat ass is none of your business
https://www.zerohedge.com/political/under-pressure-fat-activists-nyc-bans-weight-discrimination
Under Pressure From Fat Activists, NYC Bans Weight Discrimination
It is when it is taking up my seat on a plane.
Someone's fat ass is none of your business, unless you want to shove a dick in it. While you're watching and cringing at Lizzy the Commies are running a bigger rough shod over your manipulated heads.
A recent survey found that 44% of people with obesity would change jobs to gain coverage for treatment. And more than half of workers would stay at a job they didn't like to retain that coverage, according to the survey from the Obesity Action Coalition.
"I think very much that where we were on mental health as an employee benefit 10 years ago is where we are today on metabolic health. In 10 years, employees will move with their feet to employers who cover holistic metabolic health benefits," said Isabelle Kenyon, founder and CEO of Calibrate, a digital metabolic health platform.
Increasingly, as part of this focus on metabolic health, there is excitement around new and emerging obesity medications like semaglutide (Wegovy) and tirzepatide (Mounjaro). But drugs like Ozempic and Wegovy come with a hefty price tag, at least $1,000 per month. Neither drug is covered for weight loss by most insurance plans.
Semaglutide, which is sold under the brand names Ozempic, Wegovy and Rybelsus, accounted for $10.7 billion in drug spending in 2021, up 90% over the year before, which ranked it fourth among drug expenditures, according to a study published last year in the American Journal of Health-System Pharmacy.
Last year, the American Gastroenterology Association recommended coverage of weight loss drugs for those with BMI (body mass index) over 30 or BMI over 27 with complications. Currently, about 42% of people in the U.S. are obese, or have a BMI of 30 or higher, according to CDC data.
Health plan sponsors are facing increasing pressure to cover these medications. If these drugs are used by a substantial portion of those with obesity, the increase in medical costs will be high, according to Jeff Levin-Scherz, M.D., managing director and population health leader at insurance services company Willis Towers Watson (WTW).
And these advances in game-changing obesity drugs come as employers are already facing the highest medical inflation rate in decades.
"Among our clients, about two-thirds of them are covering GLP-1 drugs for obesity, however, what we’re seeing is rapid uptake and costs that are unsustainable," Levin-Scherz said. "Coverage right now is pretty good, but if these drugs continue to be as expensive as they are now, I don’t know if we could project that they will continue to be covered this way."
https://www.fiercehealthcare.com/digital-health/employers-grapple-soaring-demand-obesity-care-benefits